Fujian Pharmaceutical Leading Enterprise & MDASH; & MDASH; Fujian Guangshengtang Pharmaceutical Co., Ltd. (hereinafter referred to as & quot; Guangshengtang & QUOT;) entered the domestic & quot; Viagra & QUOT;。

 

  Recently，Guangshengtang issued an announcement to the outside world，Received the "Pharmaceutical Clinical Test Approval", which was approved by the State Food and Drug Administration (hereinafter referred to as & quot; the State Food and Drug Administration & quot;) approved by the State Food and Drug Administration & quot;)，Layout the company's layout to improve the products of related fields，lay a more solid foundation。

 

  It is understood，In front of the 10 billion market & quot; Blue Ocean & Quot;，Many pharmaceutical companies have joined the domestic & quot; Viagra & Quot; market competition，Among them, there are many Guangyao Baiyun Mountain、Changshan Pharmaceutical、Lianhuan Pharmaceutical、Lepu Medical、Neptune Bio、Yabang Aipu Pharmaceutical、Qilu Pharmaceutical and other well -known pharmaceutical companies。At present, the & quot; Kim Ge & Quot; and the production of & quot; Wan Feile & Quot;。

 

  How does a company look at the current domestic & quot; Viagra & Quot; market competition pattern? What business strategies will we adopt in the future to achieve market layout?，"China Business Daily" reporter called to the secretary office of Guangshengtang，As of press time，No relevant reply was received。

 

  Consultation Bureau & Quot; Viagra & Quot; Blue Ocean

 

  It is understood，Citrus stake online sports bettingCitic stake sports betting appacid Westya and its tablets are developed and developed by American PFIZER Company，In 1998, it was listed in the United States for the first time by the US FDA，The product is named & quot; Viagra & Quot; (Viagra)，The first medicine to treat male erectile dysfunction in the United States。而This time，Guangshengtang's batch number is 2016L09031，Dosage form is tablet，Specification 100mg，The application is the registration of domestic drugs，Registration is classified as original chemicals category 6，Indications are suitable for the treatment of erectile dysfunction。

 

  Guangshengtang Announcement Show，April 2015，The company applies to the State Food and Drug Administration's clinical application of citrus citrate citrate citrate citrates and obtained acceptance，and further represent，After the company obtains the clinical approval, the human biological equivalent (BE) test will be carried out as soon as possible as soon as possible。

 

  In the third quarterly report of 2016，Guangshengtang once said，Non -Pharmaceutical Research，It is currently in the production application approval stage，Then，On November 14th, the company received the "Pharmaceutical Clinical Test Approval" approved by the State Food and Drug Administration。

 

  According to the announcement of Guangshengtang，Ere dysfunction (ED) is a common disease for men aged 40 to 70。In the past few decades，With the deepening of research，The understanding of the disease is also gradually increasing。According to conservative estimates，About 100 million men in the world have different degrees of erectile dysfunction，About 20 million patients with erectile dysfunction in my country，At present, it is considered to be more than 3/4 of patients with all erectile dysfunction.。

 

  For the positive role of the market for the company's operations for the domestic & quot; Viagra & Quot;，Guangshengtang mentioned many times in the annual report that it can & quot; rich product line，Enhance market competitiveness & quot;，& quot; The company researchs and develops citrate citrates and its tablets，will produce better economic and social benefits。Project progress will arrange products for the company to improve related fields，lay a more solid foundation。& quot;

 

  Shi Lichen, the person Stake Sports Bettingin My stake betting appcharge of Beijing Dingchen Medical Management Consultation Center, believes，Guangshengtang's interventiStake Sports Bettingstake sports betting appon & quot; Viagra & QUOT; Market is a useful attempt for its business strategy，But for & quot; Viagra & Quot;，Its marketing strategy will occupy the dominant position，Adopting a suitable marketing strategy will bring good operating income to the company。

 

  but，As an old pharmaceutical company，Guangshengtang involved this time & quot; Viagra & Quot; Market，It will also face technology、Approval、Policy and other factors such as the impact and fierce market competition。

 

  This time，Guangshengtang's imitation of citrate citrate Sidi Nainer will face the risk of too long approval，In January this year，Guo Yunpei, the vice chairman of the China Medical Enterprise Management Association, said in an interview with the Guangzhou Daily，Compared with innovative medicines，A longer review time for generic drugs。The clinical review time of a generic drug average 3-4 years average，Listing approval also takes so long。A generic drug from submitting clinical application to obtaining listing approval，It is necessary to use six or seven years or even 89 years。Delayed approval，Extended listing time，Cooking many pharmaceuticals funds、Production line idle。& quot; China’s generic drug approval is too difficult，can be said to be the hardest in the world。& quot;

 

  and in the announcement of Guangshengtang, it is also frank，& quot; due to the particularity of drug development，Drugs will be technical from clinical trials to application for production、Approval、Policy and other factors influence，Clinical trial progress and results、Future product competition situation has many uncertainty。& quot;

 

  Many pharmaceutical companies & quot; grabbing & quot;

 

  It is understood，American & Quot; Viagra & Quot; Original & Quot; Viagra & Quot;，Long -term exclusive market share，The share exceeds 60 %。Until 2014 patent protection failure，Many domestic pharmaceutical companies that target the anti -ED drug market have only begun to join & quot; Viagra & quot;，Among them, there are many Baiyun Mountain、Changshan Pharmaceutical、Qilu Pharmaceutical and other well -known pharmaceutical companies。

 

  2014，Baiyunshan Pharmaceutical General Factory of Guangyao Group handed over 20 companies to the State Drug Administration Stake Sports Bettingstake sports betting appon & quot; Viagra & QUOT;，Current，& quot; Viagra & Quot; Imitation drugs have only two，Except Bai Yunshan & Quot; Jin Ge & Quot;，And Jiangsu Yabang Aibon Pharmaceutical's & Quot; Wanfei & Quot;。As the first country in China, the country's approval was Bai Yunshan & quot;，The first year of listing of listing is 700 million yuan。& quot; Great success of Jin Ge & Quot;，Also allowing domestic pharmaceutical companies to accelerate & quot; Viagra & Quot;。Jiangsu Yabang Aibron Pharmaceutical developed & quot; Wan Feile & Quot;，Put the goods in pharmacies across the country。

 

  In addition，Zhuhai Biochemical Pharmaceutical、Hebei Changshan Pharmaceutical and other 10 companies are also waiting for the approval of & quot; Viagra & Quot;，In the future, there may be more & quot; domestically produced Viagra & Quot; add this new & quot; blue ocean & quot; competition。

 

  Statistics of Guoxin Securities，The number of domestic ED patients is about 140 million people，Suppose 30%of them receive treatment，Number of people will reach 42 million people，Assume that patients with ED who are treated can use drugs multiple times a year，In the future, the potential market size of China is expected to reach 10 billion yuan，Compared with the current market size of about 1 billion yuan in regular ED therapy drugs，With a potential growth space of about 10 times。

 

 But，& quot;，Need to from the price、Channel and other big articles。& quot; Liu Yaming, senior analyst of Founder Securities and pharmaceutical industry, said。

 

  Counseling Bureau & Quot; Behind the Ge Ge & Quot;，Guangshengtang is also facing difficulties in the decline in the sales of the main product。It is understood，Guangshengtang is the only company in China that can produce three preferential selection of nucleoside anti -hepatitis B virus at the same time，Its three main products of Aganding (Adefir esters)、He Ganding (Lamif) and Enshing (Endi Cavavir) brought rich performance revenue to the company，More than 90 % of the company's main income。

 

  But，According to the company's 2016 annual report，The company realized total operating income of 149.297 million yuan，increased by 3.56%over the same period last year; net profit attributable to shareholders of listed companies was 40.751 million yuan，decreased by 22.60%compared to the same period last stake online sports bettingyear。stake sports betting appAmong them, Ennanting's sales income is 102.62 million yuan，increased by 23.23%over the same period last year; A -Gump's sales revenue was 32.9653 million yuan，decreased by 18.46%compared to the previous year; He Ganding's sales revenue was 13.4256 million yuan，decreased by 33.25%over the previous year。

 

  For the reasons for the decline in main business income，Announcement disclosure，& Quot; With the universal use and market share of Entica in the antiviral drug market in hepatitis B，The price of Norofovir ester decreases and gradually enters medical insurance in various provinces，Adefir ester、Lamifding's dosage gradually decreases。& quot; And further think，& quot; There are more manufacturers producing similar products in China，Nucleoside anti -hepatitis B virus drug market competition is even more intense。& quot;

 

  This，Shi Lichen thinks，Current & quot; Viagra & Quot; market development prospects，The key is to increase publicity，As a & quot; New Ding & Quot;，Guangshengtang is still lacking in market visibility。